Text size :

10 years of extended neonatal screening, Uniamo: “The challenge is to update the panel”

ADNKRONOS

November 11, 2026

Rome, Nov 11. (Adnkronos Health) – 10 years after the approval of Law 167/2016, the event ‘Extended Neonatal Screening: Achievements, New Challenges, and Opportunities’, promoted by Uniamo, the Italian Federation for Rare Diseases, was held today in Rome, in the Crestini Hall of Isma. The morning session, moderated by the director of the National Centre for Rare Diseases, Maria Luisa Scattoni, and by the president of Uniamo, Annalisa Scopinaro – a note informs – was an opportunity to retrace the process that led to the approval of a historic law for our country in 2016 and to foster a discussion on still open issues. The meeting took place a few weeks after the publication in the Official Gazette of the update to the Essential Levels of Assistance (LEA), which finally made effective the expansion of pathologies foreseen by the 2019 amendment. The national panel has increased from 49 to 58 pathologies: a result that consolidates the Italian model, among the most advanced in Europe, and standardizes access throughout the country.

At the opening, President Scopinaro focused on the value of Extended Neonatal Screening (Sne) in terms of equitable access: “Law 167/2016 has expanded a public health program that improves every year” and “has saved” thousands of children. “The challenge today – she continued – is to promptly update the national panel, without possibly having to wait for the LEA update times. If the Ministry’s working group deems a pathology suitable, it should enter the panel as a pilot project and be subject to screening in all Regions. Sne will remain a model only if it continues to guarantee the same possibilities for early diagnosis and access to therapies.”

The first round table was dedicated to recounting the two different parliamentary processes which, driven by patient associations, led to the approval of the law in 2016 and its subsequent expansion in 2019. Many exponents of politics and institutions who collaborated in achieving this goal were present at the event: Lisa Noja, currently a councilor in the Lombardy Region; Domenica Taruscio, former director of the National Centre for Rare Diseases at the National Institute of Health; Senator Paola Binetti and the Honorable Leda Volpi. Senator Paola Taverna, the first signatory of Law 167/2016, spoke about the process that led to the approval of the norm: “Ten years ago, as the first signatory of Law 167, I fought a battle born from a simple principle: every child must have the same opportunities for diagnosis and care, wherever they are born – she stated – It was an achievement built over 3 years of work, together with families and associations, fundamental protagonists of this journey. Today, that law has saved many small lives and has made Italy a reference point in Europe. But we cannot stop: research moves faster than bureaucracy. Timely updates to the screening panel and adequate structures in all Regions are needed to guarantee diagnosis and care. Because neonatal screening is not a cost, but an investment in life and the future.”

Jiji Press

Related

Page TOP